Scala Biodesign: embedding biologic design into pharma R&D workflows

Backed by a $16 million series A announced last month, Weizmann Institute spinout Scala Biodesign is developing a biology- and physics-informed AI platform for biologics design that it says can generate optimized candidates in a single round from limited starting data, and is positioning the technology for use by experimental scientists in pharma R&D.

The Tel Aviv-based biotech’s platform, ScalaOS, combines evolutionary principles, atomistic modeling, large language models and generative AI in modality-specific models for proteins, antibodies, enzymes and vaccines. By working across multiple modalities, Scala Biodesign Ltd. differs from many AI biologics companies that focus on a single molecular class...